Penserra Capital Management’s Pacira BioSciences PCRX Stock Holding History

Penserra Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-24,342	Closed	-$1.86M	–	1476
2022 Q1	$1.86M	Buy	+24,342	New	+$1.62M	0.04%	348
2021 Q4	–	Sell	-1,020	Closed	-$57K	–	1500
2021 Q3	$57K	Buy	1,020 +20	+2%	+$1.15K	﹤0.01%	1019
2021 Q2	$60K	Buy	1,000 +20	+2%	+$1.27K	﹤0.01%	951
2021 Q1	$68K	Sell	980 -15	-2%	-$1.07K	﹤0.01%	766
2020 Q4	$59K	Buy	995 +629	+172%	+$36.8K	﹤0.01%	671
2020 Q3	$22K	Buy	+366	New	+$21.3K	﹤0.01%	728

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Penserra Capital Management's PCRX Position: Q2 2022 in Review

Penserra Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2022, closing a stake of 24,342 shares — an estimated $1.86M sold.

Penserra Capital Management first reported a position in PCRX in Q3 2020 and held it in 6 quarters. The position peaked at $1.86M in Q1 2022. 284 funds tracked by Wall St. Rank hold PCRX as of Q2 2022.

Penserra Capital Management reported no remaining Pacira BioSciences position as of Q2 2022 after selling out during the quarter.
Penserra Capital Management sold 24,342 Pacira BioSciences shares in Q2 2022, an estimated $1.86M.
Penserra Capital Management first reported a position in Pacira BioSciences in Q3 2020 and held it in 6 quarters.
Penserra Capital Management's Pacira BioSciences position peaked at $1.86M in Q1 2022.
284 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2022.

Based on Penserra Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.